{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:44:02Z","timestamp":1761057842803},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.eururo.2003.11.002","type":"journal-article","created":{"date-parts":[[2003,12,2]],"date-time":"2003-12-02T12:09:41Z","timestamp":1070366981000},"page":"613-619","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin-2, Interferon-\u03b1 and 5-Fluorouracil Immunotherapy for Metastatic Renal Cell Carcinoma: The All Ireland Experience"],"prefix":"10.1016","volume":"45","author":[{"given":"M.F","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Bredin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.E.D","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2003.11.002_BIB1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.1994.12.1.206","article-title":"Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy","volume":"12","author":"Rabinovitch","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-5347(17)57082-2","article-title":"Natural history of metastatic renal carcinoma: a computer analysis","volume":"120","author":"de Kernion","year":"1978","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB3","first-page":"199","article-title":"Chemotherapy of renal cell cancer","volume":"12","author":"Yagoda","year":"1989","journal-title":"Semin. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.271.12.907","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2003.11.002_BIB5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/0140-6736(90)93039-R","article-title":"Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies","volume":"335","author":"Atzpodien","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2003.11.002_BIB6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","article-title":"The treatment of advanced renal cell cancer with high-dose oral thalidomide","volume":"85","author":"Stebbing","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.eururo.2003.11.002_BIB7","doi-asserted-by":"crossref","first-page":"A383","DOI":"10.1016\/S1569-9056(03)80389-5","article-title":"A phase I\/II trial with chimeric monoclonal antibody WX-G250 in combination with low dose interleukin-2 for patients with metastatic renal cell carcinoma","volume":"2","author":"Bleumer","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000052353","article-title":"Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group","volume":"37","author":"Rogers","year":"2000","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.10783","article-title":"Thirteen-year, long-term efficacy of interferon 2\u03b1 and interleukin-2 based home therapy in patients with advanced renal cell carcinoma","volume":"95","author":"Atzpodien","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2003.11.002_BIB10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-5347(01)66527-3","article-title":"Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients","volume":"155","author":"Hanninen","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0022-5347(01)65926-3","article-title":"Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-\u03b1 and 5-fluorouracil","volume":"156","author":"Hofmockel","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1464-410X.1996.09573.x","article-title":"A phase II study of interferon-\u03b1, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: clinical data and laboratory evidence of protease activation","volume":"77","author":"Joffe","year":"1996","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB13","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/0959-8049(93)90617-O","article-title":"Interleukin-2 in combination with interferon-\u03b1 and 5-fluorouracil for metastatic renal cell cancer","volume":"29","author":"Atzpodien","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.eururo.2003.11.002_BIB14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2003.11.002_BIB15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eururo.2003.11.002_BIB16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","article-title":"A postoperative prognostic nomogram for renal cell carcinoma","volume":"166","author":"Kattan","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.11.002_BIB17","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1200\/JCO.2002.05.111","article-title":"Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma","volume":"20","author":"Zisman","year":"2002","journal-title":"J. Clin. Oncol."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803005700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803005700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T16:53:30Z","timestamp":1550336010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283803005700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0302283803005700"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2003.11.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}